/IMPL

IMPL Stock - Impel Pharmaceuticals Inc.

Q: What is the analyst price target for IMPL?

Analyst price target information is not currently available for IMPL.

Q: What is IMPL's market cap?

Market capitalization information is not currently available for IMPL.

Healthcare|Biotechnology|NASDAQ

$0.04-27.27%

$0.01 (-27.27%) • Dec 20

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.04

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for IMPL

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.17

52W High$4.20

52W Low$0.02

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019
Revenue	$12.65M	$668,000	N/A	N/A
Gross Profit	$6.16M	$-23,000	N/A	N/A
Gross Margin	48.7%	-3.4%	N/A	N/A
Operating Income	$-83,184,000	$-71,486,000	$-45,334,000	$-41,566,000
Net Income	$-129,440,000	$-76,536,000	$-45,798,000	$-41,859,000
Net Margin	-1023.1%	-11457.5%	N/A	N/A
EPS	$-5.52	$-5.24	$-3.49	$-3.19

Company Overview

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Visit Website

Earnings History & Surprises

IMPL

Beat Rate

36%

Last 11 quarters

Avg Surprise

-15.1%

EPS vs Estimate

Beats / Misses

4/7

Last 12 quarters

Latest EPS

$-0.58

Q4 2023

EPS Surprise History

Q1 22

-24.4%

$-1.07vs$-0.86

Q2 22

-8.3%

$-1.17vs$-1.08

Q3 22

+3.5%

$-1.09vs$-1.13

Q4 22

-50.6%

$-1.31vs$-0.87

Q1 23

+6.7%

$-0.97vs$-1.04

Q2 23

-41.1%

$-1.27vs$-0.90

Q3 23

+52.3%

$-0.31vs$-0.65

Q4 23

-61.1%

$-0.58vs$-0.36

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2024	Mar 22, 2024	—	—	—	—
Q4 2023	Nov 14, 2023	$-0.36	$-0.58	-61.1%	✗ MISS
Q3 2023	Aug 18, 2023	$-0.65	$-0.31	+52.3%	✓ BEAT
Q2 2023	May 12, 2023	$-0.90	$-1.27	-41.1%	✗ MISS
Q1 2023	Mar 24, 2023	$-1.04	$-0.97	+6.7%	✓ BEAT
Q4 2022	Nov 14, 2022	$-0.87	$-1.31	-50.6%	✗ MISS
Q3 2022	Aug 15, 2022	$-1.13	$-1.09	+3.5%	✓ BEAT
Q2 2022	May 16, 2022	$-1.08	$-1.17	-8.3%	✗ MISS
Q1 2022	Mar 24, 2022	$-0.86	$-1.07	-24.4%	✗ MISS
Q4 2021	Nov 15, 2021	$-0.82	$-1.24	-51.2%	✗ MISS
Q3 2021	Aug 16, 2021	$-0.59	$-0.79	-33.9%	✗ MISS
Q2 2021	Jun 7, 2021	$-0.93	$-0.54	+41.9%	✓ BEAT
Q4 2020	Dec 31, 2020	—	$-1.07	—	—
Q3 2020	Sep 30, 2020	—	$-0.69	—	—
Q2 2020	Jun 30, 2020	—	$-0.98	—	—
Q1 2020	Mar 31, 2020	—	$-0.74	—	—

Frequently Asked Questions about IMPL

What is IMPL's current stock price?

Impel Pharmaceuticals Inc. (IMPL) is currently trading at $0.04 per share. The stock has moved -27.27% today.

What is the analyst price target for IMPL?

No analyst price targets are currently available for this stock.

What sector is Impel Pharmaceuticals Inc. in?

Impel Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is IMPL's market cap?

Impel Pharmaceuticals Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does IMPL pay dividends?

No, Impel Pharmaceuticals Inc. does not currently pay a dividend to shareholders.